There are currently 1974 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
An Extension Study for Patients Previously Enrolled in Studies with Pelabresib
NCT06401356
Recruiting
The purpose of this study is: 1. To provide continued pelabresib treatment to patients who have previously received pelabresib in a parent study and continue collecting safety and efficacy information 2. To evaluate the overall survival and leukemia-free survival of patients who discontinued placebo or pelabresib treatment in pelabresib parent studies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Northwestern Memorial Hospital (Oncology), Chicago, Illinois
Conditions: Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Register for Updates
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
NCT04821141
Recruiting
Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6 months versus a wait list control. Two risk factors for development of breast cancer will be studied pre-study and after 6 months: fibroglandular volume (FGV) on mammogram as assessed by Volpara software and proliferation by Ki-67 immunocytochemistry in benign breast tissue acquired by random periareolar fine nee... Read More
Gender:
FEMALE
Ages:
Between 45 years and 64 years
Trial Updated:
12/16/2024
Locations: Northwestern Medical Center, Chicago, Illinois
Conditions: Risk Reduction, Breast Cancer
Register for Updates
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
NCT05184335
Recruiting
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/16/2024
Locations: Reviva site, Chicago, Illinois
Conditions: Schizophrenia
Register for Updates
Telephone Support in Advanced Gastrointestinal Cancer
NCT06532877
Recruiting
The goal of this clinical trial is to see if telephone support programs help patients and their family caregivers adjust to advanced gastrointestinal cancer. A new telephone counseling program that involves practicing strategies for managing stress and symptoms will be compared to a telephone program involving education on quality-of-life issues and psychosocial support. The main questions it aims to answer are: Does our telephone counseling program lower the negative impact of patients' fatigu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Northwestern Medicine, Chicago, Illinois
Conditions: Gastrointestinal Neoplasm Malignant, Caregiver Burden
Register for Updates
Prospective Multisite Study of Quality of Life in Pediatric Intestinal Failure
NCT04629014
Recruiting
This study proposes to quantify and describe the quality of life of children with intestinal failure, and to identify the medical and socio-economic factors that impact this quality of life, using data from multiple multidisciplinary intestinal failure centers across the United States and Canada specializing in the care of these participants.
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
12/14/2024
Locations: Lurie Children's Hospital, Chicago, Illinois
Conditions: Pediatric Intestinal Failure
Register for Updates
VIBRANT: VIB4920 for Active Lupus Nephritis
NCT05201469
Recruiting
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: University of Chicago, Department of Medicine: Rheumatology, Chicago, Illinois
Conditions: Lupus Nephritis
Register for Updates
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT05990426
Recruiting
Endometrial cancer is the most common gynecologic cancer and ovarian cancer is the most lethal. The management of both advanced cancers is a combination of chemotherapy and surgery. Standard of care chemotherapeutic treatment for uterine and ovarian cancers is toxic and severely disruptive to the patient's quality of life with the potential for devastating short and long-term side effects. The role of fasting and ketogenic diets has been evaluated in a mixed cancer population and previously show... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Ovary Cancer, Endometrial Cancer, Uterine Cancer
Register for Updates
International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
NCT04496687
Recruiting
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Northwestern Medicine, Chicago, Illinois
Conditions: Spontaneous Coronary Artery Dissection
Register for Updates
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814
Recruiting
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.
Gender:
MALE
Ages:
Between 4 years and 14 years
Trial Updated:
12/12/2024
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Duchenne Muscular Dystrophy
Register for Updates
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
NCT03511118
Recruiting
Over half of women in the US who are breastfeeding their infants take prescription drugs. You are being asked to participate in this study because you are breastfeeding your infant and are currently taking, as part of your medical care, at least one of the drugs we are studying. We are interested in studying drugs commonly prescribed to women who are breastfeeding so we can learn more about the amount of drug that is transferred to breastmilk and estimate how much of drug that is consumed by bre... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/12/2024
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Register for Updates
Inpatient Stroke Recovery Using Sensors
NCT04219670
Recruiting
This observational trial seeks to assess the feasibility of using non-invasive, portable, real-time body-worn sensors to continuously monitor, quantify, and interpret recovery during inpatient treatment of stroke
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Shirley Ryan AbilityLab, Chicago, Illinois
Conditions: Stroke
Register for Updates
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
NCT04187105
Recruiting
Pre-transplant conditioning will include targeted total marrow irradiation (TMI) at a dose of 6Gy. Graft-versus-host disease prophylaxis will include cyclophosphamide 50 mg/kg on Day +3 and 4 along with tacrolimus and mycophenolate mofetil
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/11/2024
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Acute Leukemia, MDS
Register for Updates